Open an account

Bluejay Diagnostics

BJDX · NASDAQ

$0.6705−$0.0259 (−3.72%)TodayMarket closed ·
Prev close $0.6964

About BJDX

Bluejay Diagnostics, Inc. operates as a diagnostic company. The company is headquartered in Acton, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2021-11-10. The company develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. The company is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.

Employees
5
Headquarters
Acton, Massachusetts
Listed
Nov 10, 2021
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
bluejaydx.com

BJDX key statistics

Market cap
3.00M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
762.72K
Volume
48.77K
Open price
$0.6814
High today
$0.6945
Low today
$0.6651
52 Week high
$10.74
52 Week low
$0.695

Bluejay Diagnostics (BJDX) at a glance

As of Oct 20, 2026, Bluejay Diagnostics (BJDX) shares are priced at $0.6705, giving the company a market cap of 3.00M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.6651 and $0.6945. The current price is 0.8% above the day's low and 3.5% below its high.

Volume so far is 48.77K shares, below the average of 762.72K shares a day.

Over the past year Bluejay Diagnostics has ranged from $0.695 to $10.74, and now sits 0% of the way up that range.

Bluejay Diagnostics met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q4 FY23 it reported -$2,976.00 per share against an estimate of -$1,117.92.

BJDX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 10.9% on average.

  1. Q1 FY22: reported -$3,200.00 per share against an estimate of -$3,590.40
  2. Q2 FY22: reported -$3,200.00 per share against an estimate of -$2,611.20
  3. Q3 FY22: reported -$4,800.00 per share against an estimate of -$2,611.20
  4. Q4 FY22: reported -$3,840.00 per share against an estimate of $1,305.60
  5. Q1 FY23: reported -$3,840.00 per share against an estimate of -$1,958.40
  6. Q2 FY23: reported -$4,400.00 per share against an estimate of -$2,448.00
  7. Q3 FY23: reported -$3,328.00 per share against an estimate of -$1,330.08
  8. Q4 FY23: reported -$2,976.00 per share against an estimate of -$1,117.92

BJDX news

  • Vandana Singh

    Bluejay Diagnostics Advances Rapid Biomarker Testing For Sepsis Patients

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Lekha Gupta

    What's Going On With Bluejay Diagnostics Shares On Wednesday?

  • Vandana Singh

    Why Is Bluejay Diagnostics Stock Soaring Tuesday?

  • Market-Moving News for June 2nd

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

Similar companies

Companies in the same industry as Bluejay Diagnostics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.